$30 Billion available RIGHT NOW for victims of all asbestos-related diseases.
There is good news revealed from the survey for those with a mesothelioma cancer diagnosis: If they want to try CBD oil and/or medical marijuana in their treatment, they may be able to find a doctor who favors the idea. Doctors living in the western US are most open to the concept because medical marijuana is legal in several western states.
The American Cancer Society (ACS) states that while there are no clinical studies in people on the effects of CBD oil on cancer, there have been studies that show people who took extracts of marijuana needed fewer pain drugs. (Cancer.org)
The ACS also reports that scientists have found that THC and other cannabinoids such as CBD can slow cancer growth and cause the death of cancer cells grown in the lab. Some animal studies also show that some cannabinoids can slow cancer growth and slow the spread of some cancers.
More Clinical Studies Needed on CBD Oil and Medical Marijuana
No clinical studies have been performed on CBD oil just for pleural mesothelioma patients. But there is some evidence there could be anti-tumor properties lurking in the oil. In several animal studies, CBD has curbed the growth of glioblastoma, lung cancer, colon cancer, breast cancer, and prostate cancer.
Almost 50% of respondents to the survey stated they recommended medical marijuana to cancer patients within the last year.
It is not just CBD oil that is used today to treat mesothelioma and its symptoms. A new survey indicates that medical marijuana is getting more acceptance from physicians who treat mesothelioma. (Survivingmesothelioma.com) This development could open the door for more cancer patients to look at the plant’s potential to help with their disease.
Findings from Medical Marijuana Survey
While the American Cancer Society has stated that some cannabinoids can slow the growth of cancer, the DEA still states that marijuana and cannabinoids are Schedule I controlled substances. There should be more studies performed on the effectiveness of CBD and other cannabinoids in treating cancer. Some promising areas for future research include:
CBD oil has a reputation for offering relief from cancer symptoms, as well as cancer treatment symptoms. Several severe symptoms can be managed with CBD. In one clinical study, clinical researchers compared the results of THC and CBD on patients. The researchers found that patients that received CBD had more pain relief. Other symptoms that CBD can help with include nausea and vomiting caused by stress, chemotherapy, insomnia, and anxiety.
On the basis of the known pathogenesis of mesothelioma we proposed our immune-modulatory and anti-inflammatory based programme. IMM-101 enhances the innate immune response as well as inhibiting Th-2 responses. LDN inhibits TLR-9 expression and inflammatory cytokines, such as IL-6. This would reduce the inflammation drive and enhance immunity and hence reduce the inflammatory driven progression of carcinogenesis. This case suggests that this approach should be trialled in similar cases of mesothelioma, particularly in the third of patients with mesothelioma who, like our patient, refuse standard surgery and chemotherapy options.
Four years after the diagnosis he presented with an enlarging chest wall lesion where the original biopsy had been performed ( Fig. 2 b). A CT scan showed that there was a modest but definite progression of the left malignant pleural thickening, and a new right-sided effusion with peritoneal nodularity with enlargement of several intrathoracic nodes which had been noted on the early scans.
Following radiotherapy to his chest wall disease he took no other treatment, apart from a cannabis oil preparation, which he felt improved his symptoms following radiotherapy. CT scans from baseline to 65 months are shown ( Fig. 2 a-c).
The chest wall lump eventually broke down and responded to local radiotherapy. He then developed abdominal pain and was found to have peritoneal disease ( Fig. 2 c).
Declaration of competing interest
Unlike several other cancer types, it does not respond well to chemotherapy and surgery is very rarely curative. In addition to chemotherapy being poorly effective in many cases of mesothelioma, it is also suspected of hastening the progression of the tumour in some circumstances, a feature which is seen with some immunotherapy treatments in a minority of patients.
a) Slow progression of pleural and pulmonary disease. A) Baseline CT demonstrates a small left sided pleural effusion with a subtle nodular pleural disease posteriorly (open arrow). A pulmonary metastasis in the right upper lobe (closed arrow) measures 10mm in maximal diameter at baseline. B, C & D) CT studies at 46 months, 54 months and 65 months respectively post baseline demonstrating a slow interval progression. The pleural disease is circumferential but shows very little change from 46 to 65 months. The right lobe metastasis measures 13mm on all three studies. Fig. 2 b) New site of disease developed during treatment in left chest wall at site of previous biopsy. A) No disease seen in left chest wall at baseline CT. B) 31 months CT study demonstrates subtle soft tissue nodule (closed arrow) in left chest wall but patient asymptomatic from this site. C) 50 months CT study demonstrates marked enlargement in the left chest wall mass (open arrow) which is infiltrative within the left serratus anterior muscle. The mass is now symptomatic with new chest wall pain attributed to this disease. D) 65 months CT study demonstrates slight reduction in bulk of left chest wall disease post-radiotherapy. Fig. 2 c) New site of disease developed during treatment within the peritoneal cavity. a) No peritoneal disease at baseline. b) New subtle haziness of peritoneum (closed arrow) at 46 months. c) Progression of the peritoneal haziness in the right subphrenic space at 50 months with a small amount perisplenic ascetic fluid (asterix). C) 65 months CT study shows thickened peritoneal metastasis in right subphrenic space with an increase in ascitic fluid.
a) H+E stained section showing an epithelioid mesothelioma: tumour comprised of polygonal epithelial-like cells in a tubulopapillary and acinar growth pattern. No sarcomatoid component seen; b) Strong and diffuse cytoplasmic and nuclear staining for Calretinin indicates mesothelial nature of cells; c) WT1 shows strong nuclear staining, confirming mesothelial cells.
2. Case presentation
The importance of chronic inflammation and cancer is well known  and the pathogenic association is that chronic inflammation suppresses cell mediated immunity and enhances angiogenic and tumour growth factors. In this environment, random mutations are much more likely to survive and progress than in non-inflamed environments. An example of this is the enhanced development of colon cancer in patients with ulcerative colitis. The chronic inflammation and reduce immune surveillance allow a mutated gene (eg ras) to survive and develop further mutations, aided by growth factors.
A 64 year old male heating engineer was investigated for a persistent cough and found to have with a pleural effusion, pleural nodules and increased thoracic lymph nodes. Biopsy revealed an epithelioid mesothelioma ( Fig. 1 ). He declined standard of care treatment following his own research into the very low likelihood of cure and the potential side-effects of both the surgery and chemotherapy.